Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Amikacin for Intractable NTM Lung Disease
NCT01528930Phase 2Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- Feb 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amikacin in nontuberculous mycobacterial lung disease, sponsored by Samsung Medical Center. Planned start Feb 2012; status: withdrawn.
02
Drugs
amikacin
03
Conditions
nontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on NCT01528930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01528930.